The EATG is involved in the IMI-funded EFOEUPATI Project (Ensuring the Future of EUPATI – the European Patients’ Academy on Therapeutic Innovation) and especially in the work related to sustainability and future business plan for EUPATI. The overall goal is to ensure that the outcomes of EUPATI and its core activities remain sustainable.
The work package team had a meeting on 1 July 2019 in Basel, Switzerland, to discuss the suggested sustainability model, together with representatives from the EUPATI National Platforms. The proposed model will be submitted at the end of August and the next step is designing a detailed business plan. The EATG will stay actively involved in the project and support the business plan development and its implementation – also in its role as a partner in EUPATI.
The EATG has been part of EUPATI since its launch in 2012 and has played a key role as a community partner in developing and executing the EUPATI Patient Expert Training Course and the multilingual public Toolbox.
The training course is a mixture of independent e-learning coursework and face-to-face training events over a 14-month period. So far 150+ patient experts have graduated over 3 courses. Registration for the 4th course will start this year. The future EUPATI course will require participants to contribute a small share of the costs. A support scheme will be in place for those who require financial assistance.
The toolbox covers medicines R&D in more than 4,000 content items in articles, PowerPoint slide sets, infographics and fact sheets. This information is not medicine- or disease-specific. Users can access the Toolbox information in nine languages with three additional languages in translation (Portuguese, Romanian, Swedish). Recently, the toolbox reached 2 million users!
EUPATI continues to evolve. In 2018, the EUPATI Steering group voted to expand the scope of EUPATI from offering education on medicines R&D to patients via the EUPATI expert training course and the public via the EUPATI toolbox, to support meaningful patient engagement through education for all stakeholders involved in n medicines R&D. EUPATI as a training provider will thus address a wider audience including pharmaceutical industry and academia (at a later stage also regulators and HTAs) to close the current gap of no consistent, structured and recognised training being available to professionals working in patient relations/engagement management and operational roles looking to work with patients. The first course of this kind will be organised in November 2019.
To summarise, EUPATI’s current focus is as follows:
We focus on education and training to increase the capacity and capability of patients to be valuable contributors to medicines research and development by working with patients and the stakeholders they collaborate with.
For more information, see: https://www.eupati.eu/